同一期《柳叶刀》评论指出,多种原因阻碍克雅氏症难以开展传统临床试验:缺乏疗效评估手段;疾病进展快速;罕见病;招募患者困难;以及临床特征可能受多因素影响。 PRN100 从诞生到首次应用人体历时约二十年,足见该领域新药研究举步维艰。近年新药物类型(如反义寡核苷酸)、诊断指标(如 RT-QuIC)等技术发展,希望能够吸引多方投入资源,共同参与该类型疾病的药物研发工作。 题图来源:柳叶刀截图参考文献:[1]Gajdusek DC. Infectious amyloids: Subacute spongiform encephalopathies as transmissible cerebral amyloidoses. In: Fields Virology, 3rd ed, Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven, New York 1996. p.2851.[2]Gajdusek DC, Alpers MP, Gibbs CJ, Jr. Kuru: Epidemiological and virological studies of unique New Guinean disease with wide significance to general medicine. In: Hornabrook R.W., editor. Essays on Kuru. E.W. Classey Ltd.; Faringdon, UK: 1976. pp. 125–145.[3]Liberski PP. Kuru: a journey back in time from papua new Guinea to the neanderthals' extinction. Pathogens. 2013;2(3):472-505. doi: 10.3390/pathogens2030472[4]Alpers MP. Review. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos Trans R Soc Lond B Biol Sci. 2008;363(1510):3707-13. doi: 10.1098/rstb.2008.0071[5]ZIGAS V, GAJDUSEK DC. Kuru: clinical study of a new syndrome resembling paralysis agitans in natives of the Eastern Highlands of Australian New Guinea. Med J Aust. 1957;44(21):745-54. doi: 10.5694/j.1326-5377.1957.tb60287.x[6]Gajdusek DC, Gibbs CJ Jr, Alpers M. Transmission and passage of experimenal "kuru" to chimpanzees. Science. 1967;155(3759):212-4. doi: 10.1126/science.155.3759.212[7]Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science. 1977;197(4307):943-60. doi: 10.1126/science.142303[8]Alper T, Cramp WA, Haig DA, et al. Does the agent of scrapie replicate without nucleic acid? Nature. 1967;214(5090):764-6. doi: 10.1038/214764a0[9]Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136-44. doi: 10.1126/science.6801762[10]Prusiner SB. Molecular biology of prion diseases. Science. 1991;252(5012):1515-22. doi: 10.1126/science.1675487[11]Perovic S, Schröder HC, Pergande G, et al. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol. 1997;147(2):518-24. doi: 10.1006/exnr.1997.6559[12]Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology. 2004;62(5):714-8. doi: 10.1212/01.wnl.0000113764.35026.ef[13]Varges D, Manthey H, Heinemann U, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry. 2017;88(2):119-125. doi: 10.1136/jnnp-2016-313541[14]Mead S, Khalili-Shirazi A, Potter C, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurol. 2022;21(4):342-354. doi: 10.1016/S1474-4422(22)00082-5[15]Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A. 2001;98(16):9295-9. doi: 10.1073/pnas.151242598[16]Zerr I. Investigating new treatments for Creutzfeldt-Jakob disease. Lancet Neurol. 2022;21(4):299-300. doi: 10.1016/S1474-4422(22)00083-7